#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Bone disorders , especially osteoporosis , are becoming increasingly prevalent as the aging population grows , and bone fractures also occur frequently .
3-1	17-21	Bone	person|abstract[4]	new|new[4]	coref|coref	6-1|6-1
3-2	22-31	disorders	abstract[4]	new[4]	_	_
3-3	32-33	,	_	_	_	_
3-4	34-44	especially	object[5]	new[5]	_	_
3-5	45-57	osteoporosis	object[5]	new[5]	_	_
3-6	58-59	,	_	_	_	_
3-7	60-63	are	_	_	_	_
3-8	64-72	becoming	_	_	_	_
3-9	73-85	increasingly	_	_	_	_
3-10	86-95	prevalent	_	_	_	_
3-11	96-98	as	_	_	_	_
3-12	99-102	the	abstract[6]	new[6]	_	_
3-13	103-108	aging	abstract[6]	new[6]	_	_
3-14	109-119	population	abstract[6]	new[6]	_	_
3-15	120-125	grows	_	_	_	_
3-16	126-127	,	_	_	_	_
3-17	128-131	and	_	_	_	_
3-18	132-136	bone	object|object[8]	new|new[8]	coref|coref|coref|coref	5-4|14-32[82_8]|5-4|14-32[82_8]
3-19	137-146	fractures	object[8]	new[8]	_	_
3-20	147-151	also	_	_	_	_
3-21	152-157	occur	_	_	_	_
3-22	158-168	frequently	_	_	_	_
3-23	169-170	.	_	_	_	_

#Text=Osteoporosis contributes significantly to global healthcare costs , and the treatment of osteoporosis remains a great challenge .
4-1	171-183	Osteoporosis	abstract	new	coref	4-13
4-2	184-195	contributes	_	_	_	_
4-3	196-209	significantly	_	_	_	_
4-4	210-212	to	_	_	_	_
4-5	213-219	global	abstract[11]	new[11]	_	_
4-6	220-230	healthcare	organization|abstract[11]	new|new[11]	_	_
4-7	231-236	costs	abstract[11]	new[11]	_	_
4-8	237-238	,	_	_	_	_
4-9	239-242	and	_	_	_	_
4-10	243-246	the	event[12]	new[12]	_	_
4-11	247-256	treatment	event[12]	new[12]	_	_
4-12	257-259	of	event[12]	new[12]	_	_
4-13	260-272	osteoporosis	event[12]|object	new[12]|giv	coref	5-17
4-14	273-280	remains	_	_	_	_
4-15	281-282	a	abstract[14]	new[14]	_	_
4-16	283-288	great	abstract[14]	new[14]	_	_
4-17	289-298	challenge	abstract[14]	new[14]	_	_
4-18	299-300	.	_	_	_	_

#Text=Thus , new bone anabolic drugs need to be developed for the prevention and treatment of osteoporosis .
5-1	301-305	Thus	_	_	_	_
5-2	306-307	,	_	_	_	_
5-3	308-311	new	substance[17]	new[17]	_	_
5-4	312-316	bone	object|substance[17]	giv|new[17]	coref	6-22
5-5	317-325	anabolic	person|substance[17]	new|new[17]	_	_
5-6	326-331	drugs	substance[17]	new[17]	_	_
5-7	332-336	need	_	_	_	_
5-8	337-339	to	_	_	_	_
5-9	340-342	be	_	_	_	_
5-10	343-352	developed	_	_	_	_
5-11	353-356	for	_	_	_	_
5-12	357-360	the	abstract[18]	new[18]	_	_
5-13	361-371	prevention	abstract[18]	new[18]	_	_
5-14	372-375	and	_	_	_	_
5-15	376-385	treatment	event[19]	new[19]	_	_
5-16	386-388	of	event[19]	new[19]	_	_
5-17	389-401	osteoporosis	event[19]|object	new[19]|giv	coref	11-20
5-18	402-403	.	_	_	_	_

#Text=Bone morphogenetic protein 2 ( BMP2 ) is one of the most important growth factors that induce osteoblast differentiation and stimulate bone or cartilage formation .
6-1	404-408	Bone	person|abstract[22]	giv|new[22]	_	_
6-2	409-422	morphogenetic	abstract[22]	new[22]	_	_
6-3	423-430	protein	abstract[22]	new[22]	_	_
6-4	431-432	2	abstract[22]	new[22]	_	_
6-5	433-434	(	_	_	_	_
6-6	435-439	BMP2	abstract	new	coref	7-1
6-7	440-441	)	_	_	_	_
6-8	442-444	is	_	_	_	_
6-9	445-448	one	abstract[24]	new[24]	_	_
6-10	449-451	of	abstract[24]	new[24]	_	_
6-11	452-455	the	abstract[24]|abstract[26]	new[24]|new[26]	_	_
6-12	456-460	most	abstract[24]|abstract[26]	new[24]|new[26]	_	_
6-13	461-470	important	abstract[24]|abstract[26]	new[24]|new[26]	_	_
6-14	471-477	growth	abstract[24]|abstract|abstract[26]	new[24]|new|new[26]	_	_
6-15	478-485	factors	abstract[24]|abstract[26]	new[24]|new[26]	_	_
6-16	486-490	that	_	_	_	_
6-17	491-497	induce	_	_	_	_
6-18	498-508	osteoblast	event|event[28]	new|new[28]	coref|coref|coref|coref	10-12|10-11[53_28]|10-12|10-11[53_28]
6-19	509-524	differentiation	event[28]	new[28]	_	_
6-20	525-528	and	_	_	_	_
6-21	529-538	stimulate	_	_	_	_
6-22	539-543	bone	object	giv	coref	7-11
6-23	544-546	or	_	_	_	_
6-24	547-556	cartilage	object|event[31]	new|new[31]	coref|coref	7-11[35_31]|7-11[35_31]
6-25	557-566	formation	event[31]	new[31]	_	_
6-26	567-568	.	_	_	_	_

#Text=BMP2 has been widely used in the clinic to promote bone formation .
7-1	569-573	BMP2	substance	giv	coref	8-7
7-2	574-577	has	_	_	_	_
7-3	578-582	been	_	_	_	_
7-4	583-589	widely	_	_	_	_
7-5	590-594	used	_	_	_	_
7-6	595-597	in	_	_	_	_
7-7	598-601	the	abstract[33]	new[33]	_	_
7-8	602-608	clinic	abstract[33]	new[33]	_	_
7-9	609-611	to	_	_	_	_
7-10	612-619	promote	_	_	_	_
7-11	620-624	bone	object|event[35]	giv|giv[35]	coref|coref|coref|coref	10-26|20-27[137_35]|10-26|20-27[137_35]
7-12	625-634	formation	event[35]	giv[35]	_	_
7-13	635-636	.	_	_	_	_

#Text=However , the therapeutic dose of BMP2 is very expensive , and there are some life-threatening side effects that can occur with larger doses .
8-1	637-644	However	_	_	_	_
8-2	645-646	,	_	_	_	_
8-3	647-650	the	quantity[36]	new[36]	_	_
8-4	651-662	therapeutic	quantity[36]	new[36]	_	_
8-5	663-667	dose	quantity[36]	new[36]	_	_
8-6	668-670	of	quantity[36]	new[36]	_	_
8-7	671-675	BMP2	quantity[36]|abstract	new[36]|giv	coref	9-16[46_0]
8-8	676-678	is	_	_	_	_
8-9	679-683	very	_	_	_	_
8-10	684-693	expensive	_	_	_	_
8-11	694-695	,	_	_	_	_
8-12	696-699	and	_	_	_	_
8-13	700-705	there	_	_	_	_
8-14	706-709	are	_	_	_	_
8-15	710-714	some	abstract[39]	new[39]	coref	9-20[47_39]
8-16	715-731	life-threatening	abstract[39]	new[39]	_	_
8-17	732-736	side	abstract|abstract[39]	new|new[39]	coref	10-20
8-18	737-744	effects	abstract[39]	new[39]	_	_
8-19	745-749	that	_	_	_	_
8-20	750-753	can	_	_	_	_
8-21	754-759	occur	_	_	_	_
8-22	760-764	with	_	_	_	_
8-23	765-771	larger	abstract[40]	new[40]	_	_
8-24	772-777	doses	abstract[40]	new[40]	_	_
8-25	778-779	.	_	_	_	_

#Text=Hence , it is necessary to find additional agents or methods for the improvement of BMP2 itself to intensify the osteogenic effects of BMP2 .
9-1	780-785	Hence	_	_	_	_
9-2	786-787	,	_	_	_	_
9-3	788-790	it	abstract	new	cata	9-3[0_42]
9-4	791-793	is	_	_	_	_
9-5	794-803	necessary	_	_	_	_
9-6	804-806	to	abstract[42]	new[42]	_	_
9-7	807-811	find	abstract[42]	new[42]	_	_
9-8	812-822	additional	abstract[42]|person[43]	new[42]|new[43]	_	_
9-9	823-829	agents	abstract[42]|person[43]	new[42]|new[43]	_	_
9-10	830-832	or	abstract[42]	new[42]	_	_
9-11	833-840	methods	abstract[42]|abstract[44]	new[42]|new[44]	_	_
9-12	841-844	for	abstract[42]|abstract[44]	new[42]|new[44]	_	_
9-13	845-848	the	abstract[42]|abstract[44]|abstract[45]	new[42]|new[44]|new[45]	_	_
9-14	849-860	improvement	abstract[42]|abstract[44]|abstract[45]	new[42]|new[44]|new[45]	_	_
9-15	861-863	of	abstract[42]|abstract[44]|abstract[45]	new[42]|new[44]|new[45]	_	_
9-16	864-868	BMP2	abstract[42]|abstract[44]|abstract[45]|abstract[46]	new[42]|new[44]|new[45]|giv[46]	coref	9-24[0_46]
9-17	869-875	itself	abstract[42]|abstract[44]|abstract[45]|abstract[46]	new[42]|new[44]|new[45]|giv[46]	_	_
9-18	876-878	to	_	_	_	_
9-19	879-888	intensify	_	_	_	_
9-20	889-892	the	abstract[47]	giv[47]	coref	10-19[57_47]
9-21	893-903	osteogenic	abstract[47]	giv[47]	_	_
9-22	904-911	effects	abstract[47]	giv[47]	_	_
9-23	912-914	of	abstract[47]	giv[47]	_	_
9-24	915-919	BMP2	abstract[47]|substance	giv[47]|giv	coref	10-4
9-25	920-921	.	_	_	_	_

#Text=The combination of BMP2 and these small molecules can promote BMP2-mediated osteoblast differentiation and reduces the risk of its side effects in the treatment of bone diseases .
10-1	922-925	The	abstract[49]	new[49]	_	_
10-2	926-937	combination	abstract[49]	new[49]	_	_
10-3	938-940	of	abstract[49]	new[49]	_	_
10-4	941-945	BMP2	abstract[49]|substance	new[49]|giv	ana	10-19
10-5	946-949	and	abstract[49]	new[49]	_	_
10-6	950-955	these	abstract[49]|substance[51]	new[49]|new[51]	coref	11-6[62_51]
10-7	956-961	small	abstract[49]|substance[51]	new[49]|new[51]	_	_
10-8	962-971	molecules	abstract[49]|substance[51]	new[49]|new[51]	_	_
10-9	972-975	can	_	_	_	_
10-10	976-983	promote	_	_	_	_
10-11	984-997	BMP2-mediated	event[53]	giv[53]	coref	16-14[102_53]
10-12	998-1008	osteoblast	event|event[53]	giv|giv[53]	coref	23-13
10-13	1009-1024	differentiation	event[53]	giv[53]	_	_
10-14	1025-1028	and	_	_	_	_
10-15	1029-1036	reduces	_	_	_	_
10-16	1037-1040	the	abstract[54]	new[54]	_	_
10-17	1041-1045	risk	abstract[54]	new[54]	_	_
10-18	1046-1048	of	abstract[54]	new[54]	_	_
10-19	1049-1052	its	abstract[54]|substance|abstract[57]	new[54]|giv|giv[57]	coref|coref|coref|coref	11-11|15-21[89_57]|11-11|15-21[89_57]
10-20	1053-1057	side	abstract[54]|abstract|abstract[57]	new[54]|giv|giv[57]	coref	26-8
10-21	1058-1065	effects	abstract[54]|abstract[57]	new[54]|giv[57]	_	_
10-22	1066-1068	in	abstract[54]|abstract[57]	new[54]|giv[57]	_	_
10-23	1069-1072	the	abstract[54]|abstract[57]|event[58]	new[54]|giv[57]|new[58]	_	_
10-24	1073-1082	treatment	abstract[54]|abstract[57]|event[58]	new[54]|giv[57]|new[58]	_	_
10-25	1083-1085	of	abstract[54]|abstract[57]|event[58]	new[54]|giv[57]|new[58]	_	_
10-26	1086-1090	bone	abstract[54]|abstract[57]|event[58]|object|abstract[60]	new[54]|giv[57]|new[58]|giv|new[60]	coref|coref|coref|coref	14-32|26-16[175_60]|14-32|26-16[175_60]
10-27	1091-1099	diseases	abstract[54]|abstract[57]|event[58]|abstract[60]	new[54]|giv[57]|new[58]|new[60]	_	_
10-28	1100-1101	.	_	_	_	_

#Text=From a clinical perspective , these small molecules that regulate BMP2 activity provide powerful tools for the treatment of osteoporosis and fracture repair .
11-1	1102-1106	From	_	_	_	_
11-2	1107-1108	a	abstract[61]	new[61]	_	_
11-3	1109-1117	clinical	abstract[61]	new[61]	_	_
11-4	1118-1129	perspective	abstract[61]	new[61]	_	_
11-5	1130-1131	,	_	_	_	_
11-6	1132-1137	these	substance[62]	giv[62]	_	_
11-7	1138-1143	small	substance[62]	giv[62]	_	_
11-8	1144-1153	molecules	substance[62]	giv[62]	_	_
11-9	1154-1158	that	_	_	_	_
11-10	1159-1167	regulate	_	_	_	_
11-11	1168-1172	BMP2	object|abstract[64]	giv|new[64]	coref|coref	21-10|21-10
11-12	1173-1181	activity	abstract[64]	new[64]	_	_
11-13	1182-1189	provide	_	_	_	_
11-14	1190-1198	powerful	abstract[65]	new[65]	_	_
11-15	1199-1204	tools	abstract[65]	new[65]	_	_
11-16	1205-1208	for	abstract[65]	new[65]	_	_
11-17	1209-1212	the	abstract[65]|event[66]	new[65]|new[66]	_	_
11-18	1213-1222	treatment	abstract[65]|event[66]	new[65]|new[66]	_	_
11-19	1223-1225	of	abstract[65]|event[66]	new[65]|new[66]	_	_
11-20	1226-1238	osteoporosis	abstract[65]|event[66]|object	new[65]|new[66]|giv	coref	14-35[83_0]
11-21	1239-1242	and	abstract[65]|event[66]	new[65]|new[66]	_	_
11-22	1243-1251	fracture	abstract[65]|event[66]|abstract|abstract[69]	new[65]|new[66]|new|new[69]	coref|coref	15-8[0_69]|15-8[0_69]
11-23	1252-1258	repair	abstract[65]|event[66]|abstract[69]	new[65]|new[66]|new[69]	_	_
11-24	1259-1260	.	_	_	_	_

#Text=Icariin ( ICA ) ( the chemical structure is shown in
12-1	1261-1268	Icariin	substance	new	_	_
12-2	1269-1270	(	_	_	_	_
12-3	1271-1274	ICA	abstract	new	coref	15-10
12-4	1275-1276	)	_	_	_	_
12-5	1277-1278	(	_	_	_	_
12-6	1279-1282	the	abstract[72]	new[72]	_	_
12-7	1283-1291	chemical	abstract[72]	new[72]	_	_
12-8	1292-1301	structure	abstract[72]	new[72]	_	_
12-9	1302-1304	is	_	_	_	_
12-10	1305-1310	shown	_	_	_	_
12-11	1311-1313	in	_	_	_	_

#Text=Figure 1
13-1	1314-1320	Figure	object[73]	new[73]	_	_
13-2	1321-1322	1	object[73]	new[73]	_	_

#Text=) is the main active flavonoid glucoside from herbs of the genus Epimedium ; these herbs are used in traditional Chinese medicine and have long been prescribed for the treatment of bone fractures and osteoporosis as a bone-protecting agent .
14-1	1323-1324	)	_	_	_	_
14-2	1325-1327	is	_	_	_	_
14-3	1328-1331	the	substance[74]	new[74]	_	_
14-4	1332-1336	main	substance[74]	new[74]	_	_
14-5	1337-1343	active	substance[74]	new[74]	_	_
14-6	1344-1353	flavonoid	substance[74]	new[74]	_	_
14-7	1354-1363	glucoside	substance[74]	new[74]	_	_
14-8	1364-1368	from	substance[74]	new[74]	_	_
14-9	1369-1374	herbs	substance[74]|plant[75]	new[74]|new[75]	coref	14-15[78_75]
14-10	1375-1377	of	substance[74]|plant[75]	new[74]|new[75]	_	_
14-11	1378-1381	the	substance[74]|plant[75]|place[77]	new[74]|new[75]|new[77]	_	_
14-12	1382-1387	genus	substance[74]|plant[75]|abstract|place[77]	new[74]|new[75]|new|new[77]	_	_
14-13	1388-1397	Epimedium	substance[74]|plant[75]|place[77]	new[74]|new[75]|new[77]	_	_
14-14	1398-1399	;	_	_	_	_
14-15	1400-1405	these	plant[78]	giv[78]	_	_
14-16	1406-1411	herbs	plant[78]	giv[78]	_	_
14-17	1412-1415	are	_	_	_	_
14-18	1416-1420	used	_	_	_	_
14-19	1421-1423	in	_	_	_	_
14-20	1424-1435	traditional	abstract[79]	new[79]	_	_
14-21	1436-1443	Chinese	abstract[79]	new[79]	_	_
14-22	1444-1452	medicine	abstract[79]	new[79]	_	_
14-23	1453-1456	and	_	_	_	_
14-24	1457-1461	have	_	_	_	_
14-25	1462-1466	long	_	_	_	_
14-26	1467-1471	been	_	_	_	_
14-27	1472-1482	prescribed	_	_	_	_
14-28	1483-1486	for	_	_	_	_
14-29	1487-1490	the	event[80]	new[80]	coref	16-9[100_80]
14-30	1491-1500	treatment	event[80]	new[80]	_	_
14-31	1501-1503	of	event[80]	new[80]	_	_
14-32	1504-1508	bone	event[80]|object|object[82]	new[80]|giv|giv[82]	coref|coref	15-5|15-5
14-33	1509-1518	fractures	event[80]|object[82]	new[80]|giv[82]	_	_
14-34	1519-1522	and	event[80]|object[82]	new[80]|giv[82]	_	_
14-35	1523-1535	osteoporosis	event[80]|object[82]|object[83]	new[80]|giv[82]|giv[83]	coref	26-20[0_83]
14-36	1536-1538	as	event[80]|object[82]|object[83]	new[80]|giv[82]|giv[83]	_	_
14-37	1539-1540	a	event[80]|object[82]|object[83]	new[80]|giv[82]|giv[83]	_	_
14-38	1541-1556	bone-protecting	event[80]|object[82]|object[83]	new[80]|giv[82]|giv[83]	_	_
14-39	1557-1562	agent	event[80]|object[82]|object[83]	new[80]|giv[82]|giv[83]	_	_
14-40	1563-1564	.	_	_	_	_

#Text=In addition to promoting bone regeneration and repair , ICA also has many beneficial pharmacological and biological activities , including neuroprotective effects ; protective effects against atherosclerosis ; antitumor effects ; anti-inflammatory and antioxidant effects ; and improved sexual function effects .
15-1	1565-1567	In	_	_	_	_
15-2	1568-1576	addition	_	_	_	_
15-3	1577-1579	to	_	_	_	_
15-4	1580-1589	promoting	abstract[85]	new[85]	_	_
15-5	1590-1594	bone	object|abstract[85]	giv|new[85]	coref	16-18
15-6	1595-1607	regeneration	abstract[85]	new[85]	_	_
15-7	1608-1611	and	_	_	_	_
15-8	1612-1618	repair	abstract	giv	_	_
15-9	1619-1620	,	_	_	_	_
15-10	1621-1624	ICA	substance	giv	coref	16-11
15-11	1625-1629	also	_	_	_	_
15-12	1630-1633	has	_	_	_	_
15-13	1634-1638	many	abstract[88]	new[88]	appos	15-24[90_88]
15-14	1639-1649	beneficial	abstract[88]	new[88]	_	_
15-15	1650-1665	pharmacological	abstract[88]	new[88]	_	_
15-16	1666-1669	and	abstract[88]	new[88]	_	_
15-17	1670-1680	biological	abstract[88]	new[88]	_	_
15-18	1681-1691	activities	abstract[88]	new[88]	_	_
15-19	1692-1693	,	abstract[88]	new[88]	_	_
15-20	1694-1703	including	abstract[88]	new[88]	_	_
15-21	1704-1719	neuroprotective	abstract[88]|abstract[89]	new[88]|giv[89]	coref	15-29[93_89]
15-22	1720-1727	effects	abstract[88]|abstract[89]	new[88]|giv[89]	_	_
15-23	1728-1729	;	_	_	_	_
15-24	1730-1740	protective	abstract[90]	giv[90]	coref	25-19[166_90]
15-25	1741-1748	effects	abstract[90]	giv[90]	_	_
15-26	1749-1756	against	abstract[90]	giv[90]	_	_
15-27	1757-1772	atherosclerosis	abstract[90]|abstract	giv[90]|new	_	_
15-28	1773-1774	;	abstract[90]	giv[90]	_	_
15-29	1775-1784	antitumor	abstract[90]|abstract|abstract[93]	giv[90]|new|giv[93]	coref|coref	15-32[94_93]|15-32[94_93]
15-30	1785-1792	effects	abstract[90]|abstract[93]	giv[90]|giv[93]	_	_
15-31	1793-1794	;	abstract[90]	giv[90]	_	_
15-32	1795-1812	anti-inflammatory	abstract[90]|abstract[94]	giv[90]|giv[94]	coref	15-38[96_94]
15-33	1813-1816	and	abstract[90]|abstract[94]	giv[90]|giv[94]	_	_
15-34	1817-1828	antioxidant	abstract[90]|abstract[94]	giv[90]|giv[94]	_	_
15-35	1829-1836	effects	abstract[90]|abstract[94]	giv[90]|giv[94]	_	_
15-36	1837-1838	;	abstract[90]	giv[90]	_	_
15-37	1839-1842	and	abstract[90]	giv[90]	_	_
15-38	1843-1851	improved	abstract[90]|abstract[96]	giv[90]|giv[96]	coref	17-8[109_96]
15-39	1852-1858	sexual	abstract[90]|abstract[96]	giv[90]|giv[96]	_	_
15-40	1859-1867	function	abstract[90]|abstract|abstract[96]	giv[90]|new|giv[96]	_	_
15-41	1868-1875	effects	abstract[90]|abstract[96]	giv[90]|giv[96]	_	_
15-42	1876-1877	.	_	_	_	_

#Text=Several animal and cell studies have shown that treatment with ICA can increase osteogenic differentiation and reduce bone loss in vivo and in vitro .
16-1	1878-1885	Several	animal[97]	new[97]	_	_
16-2	1886-1892	animal	animal[97]	new[97]	_	_
16-3	1893-1896	and	_	_	_	_
16-4	1897-1901	cell	place|event[99]	new|new[99]	coref|coref	19-1[118_99]|19-1[118_99]
16-5	1902-1909	studies	event[99]	new[99]	_	_
16-6	1910-1914	have	_	_	_	_
16-7	1915-1920	shown	_	_	_	_
16-8	1921-1925	that	_	_	_	_
16-9	1926-1935	treatment	event[100]	giv[100]	ana	17-8[0_100]
16-10	1936-1940	with	event[100]	giv[100]	_	_
16-11	1941-1944	ICA	event[100]|substance	giv[100]|giv	coref	17-6
16-12	1945-1948	can	_	_	_	_
16-13	1949-1957	increase	_	_	_	_
16-14	1958-1968	osteogenic	event[102]	giv[102]	coref	18-10[116_102]
16-15	1969-1984	differentiation	event[102]	giv[102]	_	_
16-16	1985-1988	and	_	_	_	_
16-17	1989-1995	reduce	_	_	_	_
16-18	1996-2000	bone	object|abstract[104]	giv|new[104]	coref|coref	17-10|17-10
16-19	2001-2005	loss	abstract[104]	new[104]	_	_
16-20	2006-2008	in	abstract[104]	new[104]	_	_
16-21	2009-2013	vivo	abstract[104]	new[104]	_	_
16-22	2014-2017	and	_	_	_	_
16-23	2018-2020	in	_	_	_	_
16-24	2021-2026	vitro	_	_	_	_
16-25	2027-2028	.	_	_	_	_

#Text=The extremely low cost of ICA and its strong bone regenerative effects indicate its potential in clinical applications .
17-1	2029-2032	The	abstract[105]	new[105]	_	_
17-2	2033-2042	extremely	abstract[105]	new[105]	_	_
17-3	2043-2046	low	abstract[105]	new[105]	_	_
17-4	2047-2051	cost	abstract[105]	new[105]	_	_
17-5	2052-2054	of	abstract[105]	new[105]	_	_
17-6	2055-2058	ICA	abstract[105]|substance	new[105]|giv	coref	21-8
17-7	2059-2062	and	_	_	_	_
17-8	2063-2066	its	event|abstract[109]	giv|giv[109]	ana|ana	17-14|17-14
17-9	2067-2073	strong	abstract[109]	giv[109]	_	_
17-10	2074-2078	bone	object|abstract[109]	giv|giv[109]	coref	20-27
17-11	2079-2091	regenerative	abstract[109]	giv[109]	_	_
17-12	2092-2099	effects	abstract[109]	giv[109]	_	_
17-13	2100-2108	indicate	_	_	_	_
17-14	2109-2112	its	event|abstract[111]	giv|new[111]	_	_
17-15	2113-2122	potential	abstract[111]	new[111]	_	_
17-16	2123-2125	in	abstract[111]	new[111]	_	_
17-17	2126-2134	clinical	abstract[111]|abstract[112]	new[111]|new[112]	_	_
17-18	2135-2147	applications	abstract[111]|abstract[112]	new[111]|new[112]	_	_
17-19	2148-2149	.	_	_	_	_

#Text=The cAMP/PKA/CREB axis is a vital pathway that regulates osteogenic differentiation and mineralization .
18-1	2150-2153	The	abstract[114]	new[114]	coref	18-5[115_114]
18-2	2154-2167	cAMP/PKA/CREB	object|abstract[114]	new|new[114]	coref	19-14
18-3	2168-2172	axis	abstract[114]	new[114]	_	_
18-4	2173-2175	is	_	_	_	_
18-5	2176-2177	a	abstract[115]	giv[115]	coref	19-13[122_115]
18-6	2178-2183	vital	abstract[115]	giv[115]	_	_
18-7	2184-2191	pathway	abstract[115]	giv[115]	_	_
18-8	2192-2196	that	_	_	_	_
18-9	2197-2206	regulates	_	_	_	_
18-10	2207-2217	osteogenic	event[116]	giv[116]	coref	23-12[154_116]
18-11	2218-2233	differentiation	event[116]	giv[116]	_	_
18-12	2234-2237	and	_	_	_	_
18-13	2238-2252	mineralization	substance	new	_	_
18-14	2253-2254	.	_	_	_	_

#Text=Several previous studies have reported that PTH affects osteoblastic cells by activating the cAMP/PKA/CREB axis .
19-1	2255-2262	Several	event[118]	giv[118]	coref	20-1[123_118]
19-2	2263-2271	previous	event[118]	giv[118]	_	_
19-3	2272-2279	studies	event[118]	giv[118]	_	_
19-4	2280-2284	have	_	_	_	_
19-5	2285-2293	reported	_	_	_	_
19-6	2294-2298	that	_	_	_	_
19-7	2299-2302	PTH	abstract	new	_	_
19-8	2303-2310	affects	_	_	_	_
19-9	2311-2323	osteoblastic	object[120]	new[120]	coref	20-8[127_120]
19-10	2324-2329	cells	object[120]	new[120]	_	_
19-11	2330-2332	by	_	_	_	_
19-12	2333-2343	activating	_	_	_	_
19-13	2344-2347	the	abstract[122]	giv[122]	coref	24-11[161_122]
19-14	2348-2361	cAMP/PKA/CREB	object|abstract[122]	giv|giv[122]	coref	24-12
19-15	2362-2366	axis	abstract[122]	giv[122]	_	_
19-16	2367-2368	.	_	_	_	_

#Text=Several studies have reported that pretreatment of human mesenchymal stem cells ( MSCs ) with cAMP analogs , adenylate cyclase activators or phosphodiesterase inhibitors can enhance bone formation .
20-1	2369-2376	Several	event[123]	giv[123]	_	_
20-2	2377-2384	studies	event[123]	giv[123]	_	_
20-3	2385-2389	have	_	_	_	_
20-4	2390-2398	reported	_	_	_	_
20-5	2399-2403	that	_	_	_	_
20-6	2404-2416	pretreatment	abstract[124]	new[124]	_	_
20-7	2417-2419	of	abstract[124]	new[124]	_	_
20-8	2420-2425	human	abstract[124]|object[127]	new[124]|giv[127]	appos	20-13[0_127]
20-9	2426-2437	mesenchymal	abstract[124]|animal|object[127]	new[124]|new|giv[127]	_	_
20-10	2438-2442	stem	abstract[124]|plant|object[127]	new[124]|new|giv[127]	_	_
20-11	2443-2448	cells	abstract[124]|object[127]	new[124]|giv[127]	_	_
20-12	2449-2450	(	abstract[124]	new[124]	_	_
20-13	2451-2455	MSCs	abstract[124]|object	new[124]|giv	coref	22-15[148_0]
20-14	2456-2457	)	abstract[124]	new[124]	_	_
20-15	2458-2462	with	abstract[124]	new[124]	_	_
20-16	2463-2467	cAMP	abstract[124]|abstract|substance[130]	new[124]|new|new[130]	_	_
20-17	2468-2475	analogs	abstract[124]|substance[130]	new[124]|new[130]	_	_
20-18	2476-2477	,	abstract[124]	new[124]	_	_
20-19	2478-2487	adenylate	abstract[124]|substance|place[133]	new[124]|new|new[133]	_	_
20-20	2488-2495	cyclase	abstract[124]|abstract|place[133]	new[124]|new|new[133]	_	_
20-21	2496-2506	activators	abstract[124]|place[133]	new[124]|new[133]	_	_
20-22	2507-2509	or	abstract[124]	new[124]	_	_
20-23	2510-2527	phosphodiesterase	abstract[124]|object|substance[135]	new[124]|new|new[135]	_	_
20-24	2528-2538	inhibitors	abstract[124]|substance[135]	new[124]|new[135]	_	_
20-25	2539-2542	can	_	_	_	_
20-26	2543-2550	enhance	_	_	_	_
20-27	2551-2555	bone	object|event[137]	giv|giv[137]	coref|coref	26-16|26-16
20-28	2556-2565	formation	event[137]	giv[137]	_	_
20-29	2566-2567	.	_	_	_	_

#Text=In the present study , we combined ICA and BMP2 to promote osteogenesis for the first time .
21-1	2568-2570	In	_	_	_	_
21-2	2571-2574	the	abstract[138]	new[138]	_	_
21-3	2575-2582	present	abstract[138]	new[138]	_	_
21-4	2583-2588	study	abstract[138]	new[138]	_	_
21-5	2589-2590	,	_	_	_	_
21-6	2591-2593	we	person	acc	ana	22-1
21-7	2594-2602	combined	abstract	new	coref|none	23-4[150_0]|21-7[0_168]
21-8	2603-2606	ICA	substance	giv	coref	22-6
21-9	2607-2610	and	_	_	_	_
21-10	2611-2615	BMP2	object	giv	coref	22-13
21-11	2616-2618	to	_	_	_	_
21-12	2619-2626	promote	_	_	_	_
21-13	2627-2639	osteogenesis	abstract	new	coref	24-7[158_0]
21-14	2640-2643	for	_	_	_	_
21-15	2644-2647	the	time[143]	new[143]	_	_
21-16	2648-2653	first	time[143]	new[143]	_	_
21-17	2654-2658	time	time[143]	new[143]	_	_
21-18	2659-2660	.	_	_	_	_

#Text=We aimed to determine whether ICA could enhance the osteogenic induction of BMP2 in C2C12 cells .
22-1	2661-2663	We	person	giv	ana	23-1
22-2	2664-2669	aimed	_	_	_	_
22-3	2670-2672	to	_	_	_	_
22-4	2673-2682	determine	_	_	_	_
22-5	2683-2690	whether	_	_	_	_
22-6	2691-2694	ICA	place	giv	coref	23-7
22-7	2695-2700	could	_	_	_	_
22-8	2701-2708	enhance	_	_	_	_
22-9	2709-2712	the	abstract[146]	new[146]	_	_
22-10	2713-2723	osteogenic	abstract[146]	new[146]	_	_
22-11	2724-2733	induction	abstract[146]	new[146]	_	_
22-12	2734-2736	of	abstract[146]	new[146]	_	_
22-13	2737-2741	BMP2	abstract[146]|abstract	new[146]|giv	coref	23-9
22-14	2742-2744	in	_	_	_	_
22-15	2745-2750	C2C12	object[148]	giv[148]	_	_
22-16	2751-2756	cells	object[148]	giv[148]	_	_
22-17	2757-2758	.	_	_	_	_

#Text=We concluded that the combination of ICA and BMP2 could promote BMP2-mediated osteoblast differentiation in a dose-dependent manner .
23-1	2759-2761	We	person	giv	ana	24-1
23-2	2762-2771	concluded	_	_	_	_
23-3	2772-2776	that	_	_	_	_
23-4	2777-2780	the	abstract[150]	new[150]	coref	26-1[168_150]
23-5	2781-2792	combination	abstract[150]	new[150]	_	_
23-6	2793-2795	of	abstract[150]	new[150]	_	_
23-7	2796-2799	ICA	abstract[150]|substance	new[150]|giv	coref	24-5
23-8	2800-2803	and	abstract[150]	new[150]	_	_
23-9	2804-2808	BMP2	abstract[150]|object	new[150]|giv	coref	25-12
23-10	2809-2814	could	_	_	_	_
23-11	2815-2822	promote	_	_	_	_
23-12	2823-2836	BMP2-mediated	event[154]	giv[154]	_	_
23-13	2837-2847	osteoblast	event|event[154]	giv|giv[154]	_	_
23-14	2848-2863	differentiation	event[154]	giv[154]	_	_
23-15	2864-2866	in	_	_	_	_
23-16	2867-2868	a	abstract[155]	new[155]	_	_
23-17	2869-2883	dose-dependent	abstract[155]	new[155]	_	_
23-18	2884-2890	manner	abstract[155]	new[155]	_	_
23-19	2891-2892	.	_	_	_	_

#Text=We also found that ICA stimulates BMP2-mediated osteogenesis by activating the cAMP/PKA/CREB signaling pathway .
24-1	2893-2895	We	person	giv	_	_
24-2	2896-2900	also	_	_	_	_
24-3	2901-2906	found	_	_	_	_
24-4	2907-2911	that	_	_	_	_
24-5	2912-2915	ICA	place	giv	coref	25-3
24-6	2916-2926	stimulates	_	_	_	_
24-7	2927-2940	BMP2-mediated	abstract[158]	giv[158]	_	_
24-8	2941-2953	osteogenesis	abstract[158]	giv[158]	_	_
24-9	2954-2956	by	_	_	_	_
24-10	2957-2967	activating	_	_	_	_
24-11	2968-2971	the	abstract[161]	giv[161]	_	_
24-12	2972-2985	cAMP/PKA/CREB	abstract|abstract[161]	giv|giv[161]	_	_
24-13	2986-2995	signaling	abstract|abstract[161]	new|giv[161]	_	_
24-14	2996-3003	pathway	abstract[161]	giv[161]	_	_
24-15	3004-3005	.	_	_	_	_

#Text=Therefore , ICA is a promising candidate as an alternative for BMP2 or as a promoter for enhancing the therapeutic effects of BMP2 .
25-1	3006-3015	Therefore	_	_	_	_
25-2	3016-3017	,	_	_	_	_
25-3	3018-3021	ICA	abstract	giv	_	_
25-4	3022-3024	is	_	_	_	_
25-5	3025-3026	a	person[163]	new[163]	_	_
25-6	3027-3036	promising	person[163]	new[163]	_	_
25-7	3037-3046	candidate	person[163]	new[163]	_	_
25-8	3047-3049	as	person[163]	new[163]	_	_
25-9	3050-3052	an	person[163]	new[163]	_	_
25-10	3053-3064	alternative	person[163]	new[163]	_	_
25-11	3065-3068	for	person[163]	new[163]	_	_
25-12	3069-3073	BMP2	person[163]|object	new[163]|giv	coref	25-23
25-13	3074-3076	or	_	_	_	_
25-14	3077-3079	as	_	_	_	_
25-15	3080-3081	a	person[165]	new[165]	_	_
25-16	3082-3090	promoter	person[165]	new[165]	_	_
25-17	3091-3094	for	_	_	_	_
25-18	3095-3104	enhancing	_	_	_	_
25-19	3105-3108	the	abstract[166]	giv[166]	coref	26-8[171_166]
25-20	3109-3120	therapeutic	abstract[166]	giv[166]	_	_
25-21	3121-3128	effects	abstract[166]	giv[166]	_	_
25-22	3129-3131	of	abstract[166]	giv[166]	_	_
25-23	3132-3136	BMP2	abstract[166]|object	giv[166]|giv	coref	26-11
25-24	3137-3138	.	_	_	_	_

#Text=This combination will reduce the risk of side effects from BMP2 in the treatment of bone diseases such as osteoporosis .
26-1	3139-3143	This	abstract[168]	giv[168]	_	_
26-2	3144-3155	combination	abstract[168]	giv[168]	_	_
26-3	3156-3160	will	_	_	_	_
26-4	3161-3167	reduce	_	_	_	_
26-5	3168-3171	the	abstract[169]	new[169]	_	_
26-6	3172-3176	risk	abstract[169]	new[169]	_	_
26-7	3177-3179	of	abstract[169]	new[169]	_	_
26-8	3180-3184	side	abstract[169]|abstract|abstract[171]	new[169]|giv|giv[171]	_	_
26-9	3185-3192	effects	abstract[169]|abstract[171]	new[169]|giv[171]	_	_
26-10	3193-3197	from	abstract[169]|abstract[171]	new[169]|giv[171]	_	_
26-11	3198-3202	BMP2	abstract[169]|abstract[171]|substance	new[169]|giv[171]|giv	_	_
26-12	3203-3205	in	_	_	_	_
26-13	3206-3209	the	abstract[173]	new[173]	_	_
26-14	3210-3219	treatment	abstract[173]	new[173]	_	_
26-15	3220-3222	of	abstract[173]	new[173]	_	_
26-16	3223-3227	bone	abstract[173]|object|abstract[175]	new[173]|giv|giv[175]	_	_
26-17	3228-3236	diseases	abstract[173]|abstract[175]	new[173]|giv[175]	_	_
26-18	3237-3241	such	abstract[173]|abstract[175]	new[173]|giv[175]	_	_
26-19	3242-3244	as	abstract[173]|abstract[175]	new[173]|giv[175]	_	_
26-20	3245-3257	osteoporosis	abstract[173]|abstract[175]|object	new[173]|giv[175]|giv	_	_
26-21	3258-3259	.	_	_	_	_
